Compare Docusign Inc (DOCU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Recursion Pharmaceuticals Inc — how do they compare? Docusign Inc trades at $49.4 (market cap $9.52B), while Recursion Pharmaceuticals Inc trades at $3.37 (market cap $1.75B). The key difference: Docusign Inc is far larger — about 5.4× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| DOCU | RXRX | |
|---|---|---|
Market Cap | $9.52B | $1.75B |
Sector | Technology | Health |
52-Week High | $85.01 | $6.79 |
52-Week Low | $41.75 | $2.84 |
Enterprise Value | $8.89B | $1.17B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
